En 2024, la couverture vaccinale mondiale contre le HPV atteignait 28 % de la population cible féminine, malgré l’introduction du vaccin dans 80 % des États membres de l’OMS — un écart principalement imputable au retard d’introduction de pays à très large population tels que l’Inde, la Chine et le Pakistan. Le passage au schéma […]
Topic: 5. Financing & Gavi
Table ronde sur le financement et la viabilité financière
Les partenaires mondiaux ont convergé sur un constat partagé : l’aide publique au développement pour la santé devrait diminuer de près de 50 % entre 2021 et 2030, fragilisant les pays africains où le financement extérieur couvre plus d’un tiers — et dans certains cas plus de la moitié — des dépenses de santé. Gavi […]
Financing and Policy Dynamics in HPV Vaccine Uptake: Insights from Kenya’s Gavi Transition and Single-Dose Introduction
In Kenya, a retrospective analysis of HPV Dose 1 data from the national health information system (2019–2025) reveals a pronounced cyclical uptake pattern, with quarterly doses ranging from a low of 21,764 (Q1 2025) to a peak of 564,403 (Q4 2021), with surges consistently linked to intensified outreach campaigns and school calendar alignment and sharp […]
Does a single-dose HPV vaccine regimen deliver program cost savings? Real-world evidence from Ethiopia
In Ethiopia, a retrospective microcosting study of the late 2024 HPV vaccine multi-age cohort (MAC) campaign — targeting girls aged 9–14 across 82 health facilities in four regions — estimated the financial cost of delivering a single dose at US$0.66 and the economic cost at US$1.67 per fully vaccinated girl, excluding vaccine and immunization supply […]
Leaving 22 million girls unprotected from HPV: Impact of adopting a single-age target with low vaccination coverage in Kenya
In Kenya, a static cohort modelling study evaluated 12 HPV vaccination policy scenarios to inform the country’s cervical cancer elimination trajectory toward 2030. A prompt switch to a single-dose strategy combined with rapid coverage scale-up would avert an additional 249,700 DALYs compared with the current two-dose programme at approximately 50% coverage, while simultaneously reducing both […]
Expanding HPV vaccine Programs to Older Adolescent Girls or Young Boys: Immunization Stakeholder Perspectives in 11 Low- and Middle-Income Countries
Semi-structured interviews with 22 national immunization program managers and advisors across 11 LMICs conducted between May and August 2025 examined stakeholder perspectives on expanding HPV vaccination to older adolescent girls (15–18 years) and young boys (9–14 years). Slightly more stakeholders prioritized older girls, citing continued vaccine effectiveness post-sexual debut, independent health-seeking capacity, and evidence from […]
Financing Of Human Papillomavirus Vaccination In Africa: A Scoping Review
A scoping review of 27 studies across sub-Saharan Africa found that approximately 68% of countries rely on Gavi donations — often supplemented by the Gates Foundation, WHO, or other donors — as their primary HPV vaccine financing mechanism, with financial delivery costs ranging from US$0.27 to US$19.76 per dose depending on country, delivery modality, and […]
Financial and/or sustainability in the context of expanding target population for vaccination – Q&A
Discussion addressed the differentiated pricing landscape for HPV vaccines, clarifying that GAVI-eligible countries may access GAVI prices even for expanded target groups and that UNICEF procurement functions as an indirect pool procurement mechanism benefiting countries with small purchasing volumes. On the economics of local manufacturing, Bloem acknowledged the 10-year timeline and higher per-dose costs typical […]
Resource Mobilization and Financial Sustainability: Q&A Session
This Q&A addressed private sector engagement, civil society advocacy across government transitions, Kenya’s Gavi re-entry, and South Africa’s Mother-Daughter campaign. Zimbabwe framed HPV as a community protection investment to attract private sector support; Kenya confirmed a 2028 target for first Kenya BioVax doses. Kenya’s return to the Gavi preparatory phase followed a GNI threshold review […]
Updates in Cervical Cancer Elimination and HPV Vaccination Landscape: Q&A Session
Emily Kobayashi (Head of HPV Program, Gavi) and regional EPI managers (Guinea, Malawi, Cameroon, DRC) addressed the operationalization of the Gavi 6.0 model at the 2025 CHIC Symposium. The session clarified that the new unified grant integrates Gavi resources with national budgets and partner funding (e.g., World Bank). Key concerns focused on the 4% co-financing […]